Quantcast

Latest Lower urinary tract symptoms Stories

2010-05-18 14:37:23

In the July issue of European Urology, the scientific journal of the European Association of Urology (EAU), S. Eggener et al. discussed in a recent study the significance and impact of focal therapy for low-risk cancer patients. Since the introduction of prostate cancer screening based on prostate-specific antigen (PSA), over-treatment has increased. A significant proportion of patients diagnosed with prostate cancer have well differentiated, low-volume tumors at minimal risk of impacting...

2010-04-19 08:00:00

BARCELONA, Spain, April 19, 2010 /PRNewswire/ -- - Studies Reinforce Serious Associated Risk of Nocturia Study results discussed today at the European Association of Urology (EAU) Congress in Barcelona have reinforced the association between nocturia and a greater risk of falls and mortality. In a population-representative study in Japan by Nakagawa et al , it was concluded that adults who suffered from nocturia (defined as two or more episodes of voids/urination per night)...

2010-02-16 08:30:00

WALTHAM, Mass., Feb. 16 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, owing to longer than expected clinical development as well as competition from emerging novel injectable agents for the treatment of benign prostatic hyperplasia, Allergan's Botox will garner less market share than had been previously forecasted in the United States, France, Germany, Italy, Spain, the United Kingdom and...

2010-02-09 07:45:56

Fewer prostate cancers were detected by prostate-specific antigen (PSA) screening in the U.S. than in a European randomized trial because of lower screening sensitivity, according to a new brief communication published online February 8 in the Journal of the National Cancer Institute. To compare the PSA screening performance in a clinical trial with that in a population setting, Elisabeth M. Wever, MSc, Department of Public Health, Erasmus Medical Center, the Netherlands, and colleagues...

2010-01-06 07:00:00

WALTHAM, Mass., Jan. 6 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that GlaxoSmithKline's Duodart (the fixed-dose combination of dutasteride and tamsulosin) will earn Decision Resources' proprietary clinical gold standard status in 2013 and through 2018 for the treatment of benign prostatic hyperplasia/male lower urinary tract symptoms due to its competitive advantage in overall efficacy over...

2009-11-18 09:00:00

SEOUL, South Korea, Nov. 18 /PRNewswire/ -- Dong-A Pharmaceutical Co., Ltd. and Dong-A PharmTech, Co. Ltd. announced today that it has completed a 240 patient once-a-day dosing clinical study of udenafil, its new long acting phosphodiesterase type 5 (PDE-5) inhibitor for erectile dysfunction (ED). The multi-center study conducted in Korea was a randomized, double-blind, placebo-controlled study, designed to investigate the efficacy and safety of udenafil in patients with ED. Following a...

2009-10-20 15:16:38

According to new study published in the Journal of Urology Depression, anxiety disorders and sexual trauma have all been implicated as risk factors in lower urinary tract symptoms (LUTS) such as incontinence and overactive bladder. The exact nature of these associations is unknown. In a study published online in The Journal of Urology, researchers from the Division of Urology, Virginia Commonwealth University School of Medicine and the Hunter Holmes McGuire Veterans Affairs Hospital,...

2009-10-01 10:35:00

FRAMINGHAM, Mass., Oct. 1 /PRNewswire/ -- Solace Therapeutics, Inc., a medical device company focused on the development of non-surgical bladder control therapies announced today that it has received European CE mark approval for the Solace Intravesical System, and ISO 13485:2003 certification for the company's Framingham facility. The company is introducing its first product, an office-based therapy for Female Stress Urinary Incontinence at the International Continence Society Meeting in...

2009-09-30 06:00:00

QUEBEC CITY, Sept. 30 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported that the 043 Thorough QT (TQT) trial, which is part of the cetrorelix pamoate clinical development program in benign prostatic hyperplasia (BPH), met its primary endpoint. Results showed that cetrorelix did not increase heart rate-corrected QT interval (QTc) at either time of observed maximal...

2009-08-18 08:00:00

BELLEVUE, Wash., Aug. 18 /PRNewswire/ -- Light Sciences Oncology, Inc. (LSO) today announced the treatment of the first patients in a Phase 2 clinical trial of its innovative targeted drug treatment Aptocine(TM) (talaporfin sodium) in Benign Prostatic Hyperplasia (BPH). The Phase 2 trial expands the Aptocine BPH development program on the basis of a Phase 1 study at escalating light doses. In the open-label Phase 2 trial, Aptocine is being tested for safety and efficacy in 40 patients with...


Word of the Day
monteith
  • A large punch-bowl of the eighteenth century, usually of silver and with a movable rim, and decorated with flutings and a scalloped edge. It was also used for cooling and carrying wine-glasses.
  • A kind of cotton handkerchief having white spots on a colored ground, the spots being produced by a chemical which discharges the color.
This word is possibly named after Monteith (Monteigh), 'an eccentric 17th-century Scotsman who wore a cloak scalloped at the hem.'
Related